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Objective: To investigate fetal antigen 1 (FA1) protein within the context of human obesity and its relation with insulin
sensitivity.
Subjects: Cross-sectional study that analyses circulating levels of FA1 in two selected human cohorts: n¼ 127 men for the study
of FA1 circulating levels in the context of obesity and insulin sensitivity (Si); and n¼61 severely obese women before and after
bariatric surgery. The response in vitro to FA1 protein on human cell lines of monocytes, preadipocytes and mature adipocytes
was studied.
Measurements: Anthropometrical parameters: body mass index, waist-to-hip ratio, waist circumference, fat-free mass and fat
mass. Clinical parameters: lipid profile (high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
total cholesterol, triglycerides), glycemic profile (fasting glucose, insulin, Si, HOMA-IR (Homeostasis Model Assessment of Insulin
Resistance), cytokines (sIL-6), adipokines (adiponectin) and circulating soluble fractions of tumor necrosis factor-a receptors 1
and 2 (sTNFR1 and sTNFR2).
Results: In the obesity study, levels of FA1 in serum were found to increase with obesity. The Si index was negatively dependent
on FA1 levels. In severe obesity, serum levels of FA1 decreased 1.4-fold 6 months after bariatric surgery. In vitro assays with FA1
protein on human monocytes and adipocytes cell lines modified the expression of pro-inflammatory cytokines and adipokines
(tumor necrosis factor-a (TNFa), monocyte chemoattractant protein-1 (MCP-1), IL-6 (interleukin-6) and adiponectin).
Conclusion: FA1 serum levels were increased in obese subjects and might influence Si. The stimulatory effect of FA1 protein on
pro-inflammatory cytokines on both immune and adipose cell types could contribute to worsening the inflammatory
environment observed in obesity.
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Introduction
Obesity occurs from the increased size of individual adipose
cells due to lipid accumulation and from an increased
number of adipocytes arising from the differentiation of
adipose precursor mesenchymal stem cells to mature
adipocytes under appropriate nutritional and hormonal
signals. This precursor mesenchymal stem cell can reside in
the same adipose tissue, in the bone marrow and also in
other connective tissue compartments, and can differentiate
to adipocytes and osteoblasts, among others.
Fetal antigen 1 (FA1) has been recently identified as a
novel factor with regulatory effects on both osteoblast and
adipocyte differentiation of human mesenchymal stem
cells.1 FA1 is generated by a proteolytic cleavage of the
extracellular protein domain of the protein codified by the
gene named ‘Delta-like 1’ (dlk1, also named preadipocyte
factor 1 (pref-1)). Dlk1 gene encodes for a transmembrane
Received 8 October 2007; revised 18 February 2008; accepted 24 February
2008; published online 8 April 2008
Correspondence: Dr MR Chaco´n, Hospital Universitari de Tarragona Joan
XXIII, Unitat de Recerca, C/Dr Mallafre´ Guasch, 4, Tarragona 43007, Spain.
E-mail: mrodriguez.hj23.ics@gencat.net
International Journal of Obesity (2008) 32, 1122–1129
& 2008 Macmillan Publishers Limited All rights reserved 0307-0565/08 $30.00
www.nature.com/ijo
protein with six epidermal growth factor-like repeats in its
extracellular domain similar to other members of the Notch/
Delta/Serrate family, which participate in cell fate decisions
during development.2,3
Fetal antigen 1 has been established as an inhibitor of
adipocyte differentiation2 and has an important function in
determining cell fate decision in many differentiation
processes, including hematopoiesis,4 pancreatic islet cell,5
muscle cell,6 hepatic cell7 and dopaminergic neurons.8
Fetal antigen 1 is located in most embryonic and fetal
tissues in humans and mice, and its expression is down-
regulated in postnatal stages.9 In human adults, it is found in
the glomerulosa zone of the adrenal gland, b-cells of the
endocrine pancreas, the somatotroph cells of the pituitary
gland, the monoaminergic neurons in the central nervous
system, and in the Leydig and hilus cells of the testes and
ovaries.9,10 FA1 is also found in most biological fluids,
including urine, serum, amniotic fluid and cord serum.11
Thus, although local tissue production of FA1 is limited in
adults to the above-mentioned tissues, all tissues are exposed
to circulating FA1. Biological functions that differ from the
above-mentioned developmental effect have been recently
studied on bone marrow mesenchymal stem cells where FA1
was found to play a role in regulating cytokine gene
expression.12 Additionally, systemic effects of FA1 on bone
and fat metabolism were also determined by generating
adult mice, by hydrodynamic gene transfer procedure, which
overexpressed FA1. In this model, high levels of FA1 reduced
both bone and fat mass in a dose-dependent manner.13
Recently, FA1 has also been found to have an endocrine-
related function by regulating growth hormone expression
in mice.13,14
Dlk1 gene was confirmed in vivo as an inhibitor of adipose
tissue development, as null mice showed accelerated body
weight gain due to an increase in adipose tissue mass,
enlarged fatty liver, increased circulating levels of triglyce-
rides, cholesterol and free fatty acids.15 Conversely, trans-
genic mouse overexpressing dlk1 showed a substantial but
not a complete loss of adipose tissue, hypertriglyceridemia,
impaired glucose tolerance and decreased insulin sensitivity
(Si).
16
Given these emerging data on mouse models linking dlk1
with obesity, insulin-resistance and the recently identified
role of FA1 in murine models as an endocrine molecule
regulating fat mass in vivo, we hypothesize that FA1 could
also be related to human obesity, insulin-resistance and in
turn its inflammatory environment. For this purpose, we
have measured circulating serum levels of FA1 in a human
cohort with different degrees of obesity, and in a severe obese
cohort, before and after massive weight loss due to bariatric
surgery. We aimed to analyze the relationship of FA1 with
selected clinical and anthropometrical parameters associated
with obesity. We also aimed to analyze FA1 in relation to Si.
Additionally, in vitro FA1 effect on human monocytes and
differentiated adipocytes cell lines has been studied.
Methods
Obesity cohort
One hundred and twenty-seven Caucasian males were
included in this study. Clinical and analytical features of
the subjects are shown in Table 1. All subjects were non-
diabetic and had fasting plasma glucoseo7.0 mmol l1 levels
and 2-h post-load plasma glucose o11.1 mmol l1 after a
75-g oral glucose tolerance test following American Diabetes
Association criteria.17 With these criteria, 32% of subjects
displayed impaired fasting glucose or impaired glucose
Table 1 Clinical and analytical features (units in brackets) of the n¼127 men included in the obesity and Si study
Lean 18.5oBMIp25 (n¼27) Overweight 25oBMIp30 (n¼76) Obese 30oBMIp40 (n¼24)
Age (years) 48.5±10.3 51.6±11.5 55.0±10.7
BMI (kg m2) 23.3 (24.7) 26.9 (28.9)* 31.6 (33.9)*,#
Waist circumference (cm) 81.7±3.8 91.6±5.1* 104.7±6.9*,#
Diastolic blood pressure (mm Hg) 78.0 (82.0) 80.0 (85.0) 85.2 (90)*,#
Systolic blood pressure (mm Hg) 120.0 (127.0) 125.5 (135.7) 131.5 (140)*
Fasting glucose (mmol l1) 5.2 (5.4) 5.3 (5.6) 5.6 (5.9)*
Fasting insulin (mUI ml1) 6.7 (8.9) 7.9 (10.9)* 11.7 (17)*,#
Si (min mIU l
–1 10–4) 3.6 (4.9) 2.3 (3.0)* 1.0 (2.4)*,#
Total cholesterol (mmol l1) 5.1±0.9 5.4±1.2 5.7±0.7
Triglycerides (mmol l1) 0.8 (1.1) 0.9 (1.4) 1.1 (1.4)
HDL-C (mmol l1) 1.3±0.3 1.4±0.3 1.3±0.6
LDL-C (mmol l1) 4.0±3.5 3.4±1.0 3.8±0.6
sTNFR2 (ng ml1) 4.1 (4.6) 3.9 (5.0) 4.1 (6.2)
sTNFR1 (ng ml1) 2.3±0.6 2.5±0.7 2.0±0.6
sIL-6 (pg l1) 0.8 (0.9) 1.1 (1.5)* 1.2 (1.4)*
Adiponectin (mg ml1) 7.3 (10.3) 6.0 (7.9) 5.8 (9.1)
FA1 (ng ml1) 28.3 (34.6) 27.5 (34.6) 36.2 (49.4)*,#
Abbreviations: BMI, body mass index; FA1, fetal antigen 1; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Si, insulin
sensitivity; sIL-6, soluble interleukin-6; sTNFR1, soluble tumor necrosis factor-a receptor 1; sTNFR1, soluble tumor necrosis factor-a receptor 2. *Po0.05 compared
with lean. #Po0.05 compared with overweight.
FA1 in human obesity and insulin sensitivity
MR Chaco´n et al
1123
International Journal of Obesity
tolerance and 68% normal oral glucose tolerance. None of
the subjects were taking any medication or had any evidence
of metabolic disease other than obesity.
Subjects were classified according to body mass index
(BMI) following World Health Organization criteria.18 With
these criteria, there were 27 lean, 76 overweight and 24 obese
subjects.
Insulin sensitivity was measured using the frequently
sampled intravenous glucose tolerance test with minimal
model analysis, as already described.19 In brief, intravenous
glucose (0.3 g kg1) was administered at time 0, and insulin
(0.03 U kg1) at time þ20 min. The time courses of serum
glucose and insulin for 3 h were analyzed using the Minimal
Model Program to calculate the Si index.
Severely obese cohort
Sixty-one severely obese women scheduled for a gastric
bypass were included in this study (Table 2). Pre-operative
and 6 months post-operative anthropometrical measure-
ments were taken, and blood samples were collected.
Patients were excluded if they had suffered from an acute
major cardiovascular event in the previous 6 months, any
acute illness and current evidence of acute or chronic
inflammatory or infective diseases, or if they were taking
any medication that could alter lipidic or metabolic para-
meters. Patients receiving oral treatment for diabetes or mild
dyslipidemia before surgery discontinued all hypoglycemic
and hypolipemic agents 1 month before surgery. Patients
were always under close medical supervision to avoid any
worsening of their metabolic state.
The clinical circuit established for obtaining samples in
this cohort allowed us to perform HOMA-IR (Homeostasis
Model Assessment of Insulin Resistance) calculation, mea-
sured as previously described,20 as an insulin sensitivity test
that has a good correlation with Si, measured by minimal
model.19
Anthropometrical, clinical and analytical methods
Body mass index, waist-to-hip ratio, fat mass and fat-free
mass (bioelectric impedance, Holtain BC Analyzer, Cam-
bridge, UK), and blood pressure were measured as previously
described for healthy subjects.19
Blood samples were drawn after overnight fasting. Plasma
and serum samples were stored at –80 1C until analytical
measurements were performed, except for glucose and
HbA1c, which were determined immediately after the blood
was drawn. Serum glucose and lipidic profile (triglycerides,
total cholesterol, high-density lipoprotein cholesterol and
low-density lipoprotein cholesterol) were measured by usual
methods.
Serum insulin concentration was measured in duplicate by
monoclonal immunoradiometric assay (Coat-A-Count Insulin,
Diagnostic Products Corporation (DPC), California, USA).
Intra- and interassay coefficients of variation were 6.6 and
7.1%, respectively.
Soluble tumor necrosis factor receptor 1 was determined
by a solid phase enzyme immunoassay kit (Biosource Europe,
Fleunes, Belgium). Receptor 2 (soluble tumor necrosis factor
receptor 2), circulating soluble interleuking 6 (sIL-6), plasma
human soluble C-reactive protein (hsCRP) and plasma
adiponectin were measured as previously described.21
FA1 ELISA technique
Serum FA1 was quantified using the sandwich ELISA
(enzyme-linked immunosorbent assay) technique based on
affinity-purified polyclonal anti-FA1 antibodies as previously
described.11
Cell culture and in vitro studies
The human monocytic cell line THP-1 from the European
Collection of Cell Culture (Wiltshire, UK) was cultured in
RPMI-1640 medium (Gibco, Invitrogen Corporation,
California, USA) supplemented with 5.5 mM glucose, 10%
heat-inactivated fetal calf serum, 50 mg ml1 gentamicin,
20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) and 3 mM glutamine, and was differentiated with
160 nM phorbol 12-myristate 13-acetate (PMA) for 24 h
before use. Differentiated THP-1 was cultured for 12 h in
the same medium depleted of fetal serum and stimulated for
Table 2 Clinical and analytical characteristics (units in brackets) of the
severely obese patients (n¼ 61). Patients were all women of age (years)
43.0±8.9
Before surgery 6 months after surgery
BMI (kg m2) 47.5 (52.9) 33.4 (38.2)*
WHR 0.92±0.08 0.87±0.09*
Waist circumference (cm) 125.8±15.4 105.9±13.4*
Fat-free mass (kg) 64.1 (75.3) 59.65 (69)*
Fat mass (%) 57.0 (48.7) 46.0 (38.5)*
Fat mass (kg) 54.1±17 26±11.2*
HbA1c (%) 5.2 (6.1) 4.7 (5)*
Fasting glucose (mmol l1) 5.9 (7.3) 4.7 (5.3)*
Fasting insulin (mU l1) 44.8 (107) 29.5 (61.5)*
HOMA-IR 5.5±3.6 1.3±0.3*
Total cholesterol (mmol l1) 5.2±1.3 4.5±0.8*
Triglycerides (mmol l1) 1.6 (2.2) 1.1 (1.4)*
HDL-C (mmol l1) 1.2 (1.3) 1.3 (1.5)*
LDL-C (mmol l1) 3.1±0.9 2.7±0.9*
hsCRP (mg l1) 6.39 (9.8) 0.9 (2.7)*
sTNFR2 (ng ml1) 5.6±2.7 4.7±1.6*
sTNFR1 (ng ml1) 2.8±1.2 2.3±0.6*
Adiponectin (mg ml1) 18.4±16.5 39.8±19.6*
sIL-6 (pg l1) 4.8 (17.1) 1.89 (4)*
FA1 (ng ml1) 25.9 (31.9) 18.9 (22.9)*
Abbreviations: BMI, body mass index; FA1, fetal antigen 1; HDL-C, high-
density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment of
Insulin Resistance; LDL-C, low-density lipoprotein cholesterol; sIL-6, soluble
interleukin-6; sTNFR1, soluble tumor necrosis factor-a receptor 1; sTNFR1,
soluble tumor necrosis factor-a receptors 2; WHR, waist-to-hip ratio. *Po0.05
compared with before surgery.
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8 h with FA1 (1, 3 and 5 mg ml1). Cells were collected and
used for RNA extraction. TNF-a, IL-6 and MCP-1 gene
expressions were measured by real-time PCR relative quanti-
fication. Cytokine protein secretion in cell culture super-
natants was measured by means of ELISA kits (Biotrak ELISA
System, Amersham Biosciences, Buckinghamshire, UK).
Fetal antigen 1 protein used in this study was negative for
contamination with lipopolysaccharide and was tested by
LAL assay (Lonza Verviers, Belgium) showing 0.046 endotox-
in units per ml.
The SGBS cell line was kindly provided by Dr M Wabitsch
(University of Ulm, Ulm, Germany). This line is a human
preadipocyte cell line with a high capacity for adipose
differentiation. Cells were seeded at 3 104 cells per cm2 in a
preadipocyte medium (Advancell, Barcelona, Spain), and 3
days later, preadipocytes were stimulated with 5mg ml1 FA1
for 24 h.
In parallel, confluent SGBS preadipocytes were induced to
differentiate to mature adipocytes in adipocyte differentia-
tion medium (Advancell) containing 0.25 mM isobutyl-
methylxanthine, 1 mM dexametasone, human insulin
10 mg ml1 and a peroxisome proliferator-activated receptor
gamma (PPARg) agonist. To differentiate cells, two series of 3
days of differentiation induction with adipocyte differentia-
tion medium were carried out. Then, 50% of the medium
was replaced, every 2 days for 10 days, with adipocyte
medium (Advancell) without stimuli. Mature adipocytes
were stimulated for 24 h with 5 mg ml1 FA1 in the pre-
adipocyte medium.
Preadipocyte and adipocyte cells were collected and used
for RNA extraction. IL-6, MCP-1 and adiponectin (APM1)
gene expression were measured by real-time PCR relative
quantification.
Total RNA isolation and real-time PCR relative quantification
analysis
THP-1, preadipocytes and differentiated adipocytes from the
SGBS human cell line were extracted using the RNAsy Mini
Kit (Qiagen Science, Maryland, USA).
A quantity of 500 ng of RNA was reverse transcribed using
the transcriptor first strand cDNA Synthesis Kit (Roche
Diagnostics GmbH, Mannheim, Germany). Real-time PCR
mRNA quantification was performed using LightCycler
technology (Roche Diagnostics, Basel, Switzerland) and the
SYBR green fluorescence method. The following primers
were used: for IL-6, 50-cggtacatcctcgacgg-30 and 50-tgatgattttc
accaggc-30; for TNF-a, 50-gagcactgaaagcatgatcc-30 and 50-
gctggttatctctcagctcca-30; for MCP-1, 50-tctgtgcctgctgctcatag30
and 50-cagatctccttggccacaat-30; and for APM1, 50-cgtgatggca
gagatggc-30and 50-cgtaagtctccaatcccac-30. The housekeeping
gene used to normalize gene expression was cyclophilin A: 50-
caaatgctggacccaacac-30 and 50-gcctccacaatattcatgccttctt-30.
Fold induction and expression level for each target gene
were calculated using the comparative Ct method 2
DDCt .
Statistical analysis
Statistical analysis was performed using the SPSS/PCþ
statistical package (v. 13 for Windows; Chicago, Illinois,
USA). An adequately powered sample size was selected for
both studies. Therefore, we previously calculated the sample
size necessary to obtain a statistical power of 80%. The
number of experimental patients for the independent design
necessary was 16 for the obesity cohort and 25 for the
severely obese cohort, considering an error probability for a
two-sided test of 0.05.
For clinical and anthropometrical variables, normal dis-
tributed data are expressed as mean value±s.d., and for
variables with no Gaussian distribution, values are expressed
as median (75th percentile). Differences between groups in
clinical, laboratory parameters or plasma levels were com-
pared using either an independent sample t-test or analysis
of variance. Not normally distributed variables were loga-
rithm transformed or non-parametric tests were used when
appropriate. Differences in variables before and 6 months
after surgery and in vitro experimental data were analyzed by
a general linear model test. Associations between quantita-
tive variables were evaluated by Pearson/Spearman’s correla-
tion analysis. Correction for confounding and interacting
variables was performed using a stepwise multiple linear
regression analysis. Results are expressed as unstandardized
coefficient (B), and 95% confidence interval for B
(95%CI(B)). Statistical significance occurred if the computed
two-tailed probability value was less than 0.05.
Statement of ethics
We certify that all applicable institutional and governmental
regulations concerning the ethical use of human volunteers
were followed during this research. This study was approved
by the Ethics Committee of the Hospital.
Results
Obesity cohort
In the obesity study, levels of FA1 in serum showed
significant differences between lean and obese (P¼0.005)
and between overweight and obese (P¼0.003) subjects
(Table 1). Although no significant differences were found
between lean and overweight subjects, there is a tendency
toward increasing levels of FA1 with weight (Figure 1a).
Bivariate correlation analysis was performed to determine
the interdependence or co-relationship of clinical and
anthropometrical variables related with obesity and insu-
lin-resistance. We found that FA1 circulating levels were
positively associated with BMI, waist circumference, age,
insulin and triglycerides (r¼ 0.265, P¼0.003; r¼0.227,
P¼0.016; r¼0.262, P¼0.003; r¼0.220, P¼0.019;
r¼0.266, P¼0.003, respectively), and negatively associated
with high-density lipoprotein cholesterol and Si (r¼0.199,
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P¼0.026; r¼0.264, P¼0.003). Figure 2 shows the linear
correlation results between Si and FA1.
Then a regression model was constructed to know which
of the above correlated variables were true predictors of FA1.
In this model, FA1 was the dependent variable, and Si, age,
BMI and triglycerides were the independent variables. We
found that age (B¼0.173, P¼0.002, 95%CI(B): 0.007–0.278)
and BMI (B¼ 0.673, P¼0.005, 95%CI(B): 0.203–1.143) were
unique determinants of FA1 levels.
Finally, to corroborate the hypothesis as to whether FA1
levels could predict Si, a multiple regression analysis model
was constructed. In this model, age, FA1 and triglycerides
were included as independent variables. The result showed
that FA1 was the only determinant of Si, which means that,
in this model, FA1 is the only predictor of Si (B¼0.374,
P¼0.006, 95%CI(B): 0.593–0.155).
Severely obese cohort
Fetal antigen 1 levels were measured in a cohort of severely
obese subjects before and 6 months after massive weight loss
due to bariatric surgery. Severely obese subjects before
surgery had higher values for all the anthropometrical
measurements compared with 6 months after surgery.
Metabolic parameters (glucose, insulin and HbA1c) and
lipidic parameters showed a significant decrease after surgery
with near normal values at 6 months. Circulating pro-
inflammatory markers were elevated before surgery, as
shown by the high values of hsCRP, sTNFR2 and sIL-6.
Adiponectin displayed normal behavior in plasma increasing
with weight loss (Table 2).
Serum levels of FA1 decreased 1.4-fold after weight loss
(Po0.001) (see variation in individual cases in Figure 1b).
In bivariate correlation analysis, FA1 levels before surgery
correlated only with triglycerides (r¼0.338, P¼0.016). To
evaluate whether metabolic or pro-inflammatory parameters
could modulate FA1 circulating levels before surgery, a
multivariate regression model was constructed with FA1 as
the dependent variable, and hsCRP, sIL-6, glucose, insulin
and triglycerides as independent ones. We found that
triglyceride levels were the only determinant explaining
FA1 levels before surgery (B¼2, P¼0.008, 95%CI(B): 1.18–6.8).
While analyzing the correlations of FA1 6 months after
surgery with all the described variables, we found that FA1
correlated with age, plasma glucose levels and triglycerides
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Figure 1 (a) Box plot (each box shows the median, quartiles and extreme
values) representation of fetal antigen 1 (FA1) levels in the obesity cohort.
*P¼ 0.001 compared with lean. #P¼0.003 compared with overweight. (b)
Individual FA1 levels in the severely obese cohort before surgery (K) and 6
months after surgery (.).
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(r¼0.450, P¼0.001; r¼0.356, P¼0.005 and r¼0.295,
P¼0.04, respectively). In the regression analysis, only age
and triglycerides remained as independent determinants of
FA1 levels at the end of the follow-up period (B¼0.008,
P¼0.001, 95%CI(B): 0.03–0.012; B¼5.05, P¼0.002,
95%CI(B): 3–12.8, respectively).
To know whether FA1 decrement is predicted by weight
loss or by an improvement in metabolic parameters at 6
months, we constructed a regression model including the
decrement of values before and 6 months after surgery from
three selected variables as independent variables (decrement
of BMI, triglycerides and glucose), and FA1 decrement as the
dependent variable. The FA1 decrement in this population
was determined by the final weight loss and the improve-
ment in triglycerides levels (B¼0.394, P¼0.004, 95%CI(B):
0.146–0.642; B¼1.855, Po0.001, 95%CI(B): 1.42–2.3,
respectively).
Stimulation of THP-1, preadipocytes and differentiated
adipocytes cells with FA1 enhance cytokine production
To obtain a localized effect of FA1 on monocytes and on
preadipocytes or mature adipocytes, we tested, over a short
period of time, doses up to 5mg ml1 of FA1 in accordance
with published data.12
We tested 1, 3 and 5mg ml1 of FA1 for 8 h on a THP-1
human monocytic cell line. As shown in Figure 3a, FA1
induced gene and protein expression of cytokines MCP-1,
TNF-a (tumor necrosis factor-a) and IL-6 (interleukin-6).
We then tested the effect of 5 mg ml1 FA1 on SGBS
preadipocytes and differentiated adipocytes after 24 h in-
cubation. The results are shown in Figure 3b. FA1 only had
an effect on mature adipocytes, inducing an increase in gene
expression of MCP-1 and IL-6 and a decrease in the
expression of APM1. No stimulatory effect was seen for
TNF-a (data not shown).
Discussion
Over the years, the studies on dlk1/FA1 associated with
obesity and adipose tissue have been focused on mouse
models, mice adipose tissue or in vitro mouse cellular models.
The aim of the present investigation was to determine
whether FA1 had a similar role in human obesity, and its
relationship with its inflammatory and insulin-resistant
environment.
In the present study, we have observed that FA1 levels
increase with obesity. This data are not in accordance with
previously published data on mouse models where FA1 levels
increase with the loss of adipose tissue mass.13,15,16 However,
although this may seem counterintuitive at first, it does not
necessarily conflict with the positive relationship between
FA1 and fat mass in humans. For example, leptin mice
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knockouts are obese and mice overexpressing leptin show
less fat mass; on the contrary, obesity in humans shows
higher leptin levels which has been associated with insulin-
resistance, inflammation and disturbance homeostasis.
In our obesity cohort, we have observed a clear positive
relationship between FA1 levels and BMI and waist circum-
ference. These findings were corroborated in a regression
model where FA1 levels were found to be positively related to
age and BMI. Moreover, when we studied FA1 levels in our
severely obese cohort, before and after massive weight loss,
we observed a significant decrease in the circulating FA1
protein levels encompassed by decrements in inflammatory
markers, adipokines and atherogenic profile indicators.
Noteworthy, the severely obese cohort, composed mainly
of women, had lower FA1 levels after surgery than the male
obese cohort. In this sense, we can postulate that it could be
because of a sexual dimorphism in our populations; how-
ever, previous studies have shown no significant differences
between genders.11 Moreover, severely obese subjects after
surgery are under a high catabolic process and there are
many variables that are difficult to control. In this sense,
interpretation of findings should be undertaken individually
within each cohort.
Variable levels of FA1 have been found to be associated
with several human pathologies such as neurofibromatosis,
where FA1 was found to be elevated 5 times,22 and in renal
failure, 10 times.11 In acromegaly or growth hormone (GH)
deficiency patients, FA1 levels changed after pharmacologi-
cal treatment for GH. In these patients, pharmacological
variation in GH levels resulted in a corresponding change in
the concentration of circulating FA1.23 In vitro analysis
showed that FA1 represses GH transcription and revealing a
feedback regulatory loop to keep GH function precisely
modulated.14 Human obesity has been associated with
decreased GH secretion and low levels of insulin growth
factor-1,24 in this sense, we should expect lower levels of FA1
in obesity. However, our findings showed that FA1 levels
increase with obesity.
Human obesity is associated with a chronic low degree of
inflammation where cytokines such as IL-6, TNF-a and MCP-
1 play an important role.21,25 Similarly, changes in these
cytokine levels have been involved in the pathogenesis of
type 2 diabetes and cardiovascular diseases, both diseases
highly linked with obesity.25,26 We have observed that one of
the main effects of FA1 on human monocytes and adipocytes
cell lines in vitro is to enhance the expression of some pro-
inflammatory cytokines. In support of our findings, several
studies have shown that FA1 is also involved in the
mediation of the immunoresponse. The mechanisms con-
cerning this regulatory function and its targets have been
recently disclosed on human mesenchymal stem cells to be
mediated through nuclear factor-kB.12 Besides, we have
observed that FA1 downregulates the levels of adiponectin
expression in vitro, in agreement with our findings in the
obesity study. This is an important fact, as it is an adipokine
found to be involved in the control of fat metabolism and Si,
with direct anti-diabetic, anti-atherogenic and anti-inflam-
matory activities.27
Fetal antigen 1 has a pleiotropic function and is involved
in many developmental and differentiation processes.
Human and rat insulin b-cells have also been found to
secrete FA1. Long-term exposure of rat islets to high glucose
increases FA1 and insulin secretion, indicating that FA1 is
regulated by glucose.28 In our study on the obesity cohort,
FA1 was inversely associated with Si and was a predictor of Si
index, thus suggesting the involvement of this protein in
the peripheral action of insulin. It is difficult to confer a
pathogenic role for FA1 in the mechanisms related to
insulin-resistance because of the transversal design of our
obesity cohort; however, the experimental data in the
transgenic mice model for dlk1 showed impaired insulin-
resistance,16 which is in accordance with the above-men-
tioned clinical observations, at least in male subjects.
The contribution of human subcutaneous or visceral
adipose tissue to circulating FA1 is irrelevant because no
gene or protein expression was detected in those tissues, nor
in isolated preadipocytes or mature adipocytes (MR Chacon
et al., unpublished data), subsequently other glandular
tissues, such as adrenal gland, glandular pancreas, and so
on, may be the main source of these circulating levels.
In conclusion, our data show for the first time FA1 serum
protein in human obesity and its link to insulin-resistance.
We have demonstrated, in our cohorts, that circulating levels
of the soluble product FA1 are positively associated with BMI
and negatively with Si exerting a stimulatory effect on pro-
inflammatory cytokines both in immune and adipose cell
types that can worsen the inflammatory environment,
complicating the pathological state of the patient. The
behavior observed in our study of FA1 circulating levels with
respect to adiposity enables us to propose this protein as a
possible candidate for further investigation as an obesity
biomarker.
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